Mitf-Signal Responsive Transcription in Osteoclasts
Mitf-Signal Responsive Transcription in Osteoclasts
批准号:
7787486
负责人:
DAVID E FISHER
金额:
$28.87万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-03-01 至 2009-12-31
关键词:
Albers-Schonberg diseaseAllelesBiochemicalBone DiseasesBone ResorptionCell LineageClassificationDefectDevelopmentDimerizationDoctor of PhilosophyDominant-Negative MutationEP300 geneExhibitsGene TargetingGenesGenetic TranscriptionHelix-Turn-Helix MotifsKnockout MiceMAP Kinase GeneMacrophage Colony-Stimulating FactorMediator of activation proteinMutant Strains MiceMutationOsteoclastsPathway interactionsPeptide HydrolasesPhosphorylationPost-Translational RegulationProcessRegulationResearchRoleSerineSignal PathwaySignal TransductionStagingTFE3 geneTranscriptional Regulationbasecathepsin Kcytokinein vivomanmouse modeltranscription factor
中文摘要
描述(由申请人提供):Mitf是一种螺旋-环-螺旋转录因子,其突变可在多个物种中产生严重的骨质疏松症。来自mitf突变小鼠的破骨细胞谱系细胞发育,但似乎在大约融合阶段停止,并表现出严重的骨吸收缺陷。这种晚期发育缺陷表明,Mitf转录因子调控晚期破骨细胞分化基因,而不是谱系决定的全局调控因子。这些基因的鉴定和调控其表达的转录控制将为人类骨疾病的治疗提供重要的新靶点。我们观察到Mitf的显性阴性等位基因产生严重的骨质疏松症,而无等位基因则不会。在此基础上,我们确定了TFE3,一个相关的HLH因子,作为一个二聚化伙伴,在破骨细胞谱系中与Mitf具有相同的转录活性。Mitf和TFE3的这种重叠作用已在双空小鼠模型中得到验证。我们还证明,M-CSF是早期和晚期破骨细胞发育的重要细胞因子,可触发MAPK在保守丝氨酸上的Mitf和TFE3磷酸化,刺激它们募集共激活因子p300。这种磷酸化受体丝氨酸的突变破坏了晚期破骨细胞的分化。除了这种翻译后调控外,我们还鉴定了几个Mitf/TFE3转录靶基因,包括分泌蛋白酶组织蛋白酶K和存活基因Bcl2。体内这些基因的破坏会导致骨质疏松。Mitf/TFE3在晚期破骨细胞成熟中的重要作用为通过分析其生化调控和靶基因鉴定发现骨吸收过程的关键途径和介质提供了独特的机会。我们建议在两个具体目标中进行这种分析。第一个重点是阐明调节Mitf和TFE3表达和活性的转录和翻译后机制,从而调节晚期破骨细胞的发育和骨吸收。第二种是一种系统的方法来识别Mitf/TFE3的转录靶标,使用筛选将其生化活性与它们所在的信号通路结合起来。
英文摘要
DESCRIPTION (provided by applicant): Mitf is a helix-loop-helix transcription factor whose mutation produces severe osteopetrosis in multiple species. Osteoclast lineage cells from Mitf-mutant mice develop, but appear to arrest at approximately the fusion stage and exhibit profoundly defective bone resorption. This late developmental defect suggests that the Mitf transcription factor regulates late osteoclast differentiation genes, rather than global regulators of lineage determination. The identification of those genes and the transcriptional controls which modulate their expression stand to provide important new targets for the treatment of bone disorders in man. We observed that dominant negative alleles of Mitf produce severe osteopetrosis whereas null alleles do not. On this basis we identified TFE3, a related HLH factor, as a dimerization partner which shares transcriptional activities with Mitf in the osteoclast lineage. This overlapping role for Mitf and TFE3 has been verified in a double-null mouse model. We have also demonstrated that M-CSF, a vital cytokine for both early and late osteoclast development, triggers MAPK phosphorylation of both Mitf and TFE3 on a conserved serine, stimulating their recruitment of the coactivator p300. Mutation of this phosphoacceptor serine disrupts late osteoclastic differentiation. In addition to this post-translational regulation, we have identified several Mitf/TFE3 transcriptional target genes including the secreted protease cathepsin K, and the survival gene Bcl2. In vivo disruption of these genes results in osteopetrosis. The essential roles for Mitf/TFE3 specifically for late osteoclast maturation affords a unique opportunity to discover key pathways and mediators of the bone resorption process through the analysis of their biochemical regulation and target gene identification. We propose to carry out this analysis in two Specific Aims. The first focuses on elucidating transcriptional and post-translational mechanisms which regulate expression and activity of Mitf and TFE3, which in turn modulate late osteoclast development & bone resorption. The second represents a systematic approach to the identification of transcriptional targets of Mitf/TFE3 using screens which couple their biochemical activities to the signaling pathways in which they reside.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
MITF from control of pigmentation to melanoma risk
-
批准号:10828041
-
项目类别:
-
资助金额:$9.0万
-
财政年份:2023
-
负责人:DAVID E FISHER
-
依托单位:
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
-
批准号:10331800
-
项目类别:
-
资助金额:$36.61万
-
财政年份:2018
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:9753925
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:9376481
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:10245261
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:10570507
-
项目类别:
-
资助金额:$51.17万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:9977915
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Development of next-generation cancer functional diagnostics
-
批准号:8492572
-
项目类别:
-
资助金额:$22.71万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Administrative Core
-
批准号:8415143
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
-
批准号:10443720
-
项目类别:
-
资助金额:$33.26万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
-
批准号:9792731
-
项目类别:
-
资助金额:$151.67万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Administrative Core
-
批准号:10658866
-
项目类别:
-
资助金额:$11.43万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
-
批准号:9257289
-
项目类别:
-
资助金额:$140.77万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
-
批准号:10227092
-
项目类别:
-
资助金额:$34.14万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
-
批准号:8842005
-
项目类别:
-
资助金额:$140.55万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
-
批准号:10658849
-
项目类别:
-
资助金额:$142.84万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera
-
批准号:8415140
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
-
批准号:8415137
-
项目类别:
-
资助金额:$146.1万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
-
批准号:10443719
-
项目类别:
-
资助金额:$143.05万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Administrative Core
-
批准号:10443723
-
项目类别:
-
资助金额:$11.43万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
海外基金